3 Premium Retail Malls Owner, Technology Consulting Company and Portable Molecular Diagnostics Maker Stocks With a Strong Future Roadmap: Phoenix Mills, LTM and Molbio Diagnostics
- November 4, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Phoenix Mills, LTM and Molbio Diagnostics: ROE of 11.1% to 20.2% and FY22 to FY26 revenue CAGR of 12.7% to 31.0%. Prices as of 3 Nov 2026.
Quick Answer
The three mall, IT consulting and rapid test stocks to watch are Phoenix Mills, LTM and Molbio Diagnostics. Their return on equity ranges from 11.1% to 20.2%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.7% to 31.0%. LTM has the highest return on equity at 20.2%, while Phoenix Mills has the fastest revenue growth at 31.0% a year. Prices are based on the 3 November 2026 close, and this article is educational, not investment advice.
Mall, IT consulting and rapid test stocks give investors a way to track businesses that sit close to everyday demand in India. Phoenix Mills, LTM and Molbio Diagnostics cover a premium retail malls owner, a technology consulting company and a portable molecular diagnostics maker.
This list covers three mall, IT consulting and rapid test stocks with complete current figures: Phoenix Mills, LTM and Molbio Diagnostics. Every figure comes from the latest reported financials and the 3 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Mall, IT Consulting and Rapid Test Stocks?
Mall, IT consulting and rapid test stocks are listed companies that own and run premium retail malls, offer technology consulting and digital solutions, and make portable molecular diagnostics systems that deliver lab-grade results at the point of care. Their earnings depend on mall footfall, client technology budgets and test volumes.
Mall, IT Consulting and Rapid Test Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Phoenix Mills | 2,048.7 | 68,308 | 41.9 | 30.7 | 11.1 | 0.48 |
| LTM | 4,213 | 120,479 | 23.2 | 17.6 | 20.2 | 0.09 |
| Molbio Diagnostics | 1,350.8 | 16,605 | 101.2 | 59.6 | 14.2 | 0.38 |
On valuation, all three trade at a P/E above their industry P/E, which reflects the growth the market already expects from them. Readers comparing mall, IT consulting and rapid test stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Mall, IT Consulting and Rapid Test Stocks Have a Strong Roadmap in India?
Mall, IT consulting and rapid test stocks have a strong roadmap in India because growing organised retail, rising digital transformation work and wider access to rapid testing keep widening the market for these companies.
- Malls. Shoppers prefer premium retail spaces.
- Technology consulting. Banks and insurers modernise systems.
- Rapid diagnostics. Point of care tests reach remote areas.
Why Phoenix Mills Features Among These Mall, IT Consulting and Rapid Test Stocks
Among the mall, IT consulting and rapid test stocks on this list, Phoenix Mills owns and operates premium retail malls in major cities under the Phoenix brand and also has commercial, residential and hospitality assets.
In the June 2026 quarter, revenue grew 13.3% year on year to Rs 1,115 crore, while net profit rose 23.0% to Rs 394 crore. Revenue rose from Rs 1,558 crore in FY22 to Rs 4,594 crore in FY26, a compound annual growth rate of 31.0%.
Net profit grew from Rs 248 crore in FY22 to Rs 1,557 crore in FY26, which works out to a compound annual growth rate of 58.3%. The company has a return on equity of 11.1%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 68,308 crore. The stock trades at a P/E of 41.9, above the industry P/E of 30.7.
Roadmap: The company is adding mall space and commercial assets as consumer spending rises. Rental income linked to footfall and consumption supports earnings as the portfolio matures.
What to watch: Track consumption in its malls, new mall openings and rental growth.
Why LTM Features Among These Mall, IT Consulting and Rapid Test Stocks
Among the retail space, technology and diagnostics shares on this list, LTM, formerly LTIMindtree, is a Mumbai-based global technology consulting and digital solutions company that serves banking, insurance, manufacturing, healthcare and other industries.
The company has a return on equity of 20.2%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 120,479 crore. The stock trades at a P/E of 23.2, above the industry P/E of 17.6.
Revenue rose from Rs 26,874 crore in FY22 to Rs 43,402 crore in FY26, a compound annual growth rate of 12.7%. Net profit grew from Rs 3,950 crore in FY22 to Rs 4,983 crore in FY26, which works out to a compound annual growth rate of 6.0%.
Roadmap: The company is focused on cloud, data and artificial intelligence projects and on winning larger transformation deals from existing clients. Its link with the Larsen and Toubro group helps it reach large enterprise customers.
What to watch: Track deal wins, client additions and utilisation levels.
Why Molbio Diagnostics Features Among These Mall, IT Consulting and Rapid Test Stocks
Among the three companies on this list, Molbio Diagnostics, based in Goa, develops the Truenat platform, a portable molecular diagnostics system that delivers lab-grade PCR results at the point of care, with strong use in tuberculosis testing.
Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%.
The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6.
Roadmap: Its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.
What to watch: Order timing from public health programmes can be lumpy, so look at annual rather than single-quarter trends.
Phoenix Mills vs LTM vs Molbio Diagnostics on Key Financials
The table below sets the three mall, IT consulting and rapid test stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Phoenix Mills | 1,558 | 4,594 | 31.0% | 1,557 | 33.9% |
| LTM | 26,874 | 43,402 | 12.7% | 4,983 | 11.5% |
| Molbio Diagnostics | 782 | 1,455 | 16.8% | 164 | 11.3% |
LTM posts the highest return on equity in this group at 20.2%. LTM has the largest FY26 revenue at Rs 43,402 crore, and Phoenix Mills shows the fastest revenue growth with a 31.0% compound annual rate. A useful habit with mall, IT consulting and rapid test stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Mall, IT Consulting and Rapid Test Stocks
Every theme carries risks that deserve a check before any decision. For these mall, IT consulting and rapid test stocks, the main points are: Long-term retail space, technology and diagnostics shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Consumer spending. Sales follow festivals, incomes and consumer mood.
- Client spending. Technology budgets can vary with global conditions.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter mall, IT consulting and rapid test stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Mall, IT Consulting and Rapid Test Stocks
Mall, IT consulting and rapid test stocks work best when investors track growth, valuation and return on equity side by side. Phoenix Mills, LTM and Molbio Diagnostics each have a clear plan to grow. Based on the 3 November 2026 close, Phoenix Mills trades at Rs 2,048.7, LTM at Rs 4,213 and Molbio Diagnostics at Rs 1,350.8.
Download the Univest iOS App or Univest Android App to track mall, IT consulting and rapid test stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are mall, IT consulting and rapid test stocks?
Ans. Mall, IT consulting and rapid test stocks are listed companies that own and run premium retail malls, offer technology consulting and digital solutions, and make portable molecular diagnostics systems that deliver lab-grade results at the point of care. Their earnings depend on mall footfall, client technology budgets and test volumes. This list looks at three of them, Phoenix Mills, LTM and Molbio Diagnostics, using reported FY22 to FY26 financials and the 3 November 2026 closing prices.
Which mall, IT consulting and rapid test stocks are covered in this list?
Ans. This list covers Phoenix Mills, LTM and Molbio Diagnostics. Based on the 3 November 2026 close, Phoenix Mills traded at Rs 2,048.7, LTM at Rs 4,213 and Molbio Diagnostics at Rs 1,350.8. Their return on equity ranges from 11.1% to 20.2%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.7% to 31.0%.
Why do mall, IT consulting and rapid test stocks have a strong future roadmap in India?
Ans. Mall, IT consulting and rapid test stocks have a strong roadmap in India because growing organised retail, rising digital transformation work and wider access to rapid testing keep widening the market for these companies. The main drivers are as follows. Malls. Shoppers prefer premium retail spaces. Technology consulting. Banks and insurers modernise systems. Rapid diagnostics. Point of care tests reach remote areas. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Phoenix Mills performed financially?
Ans. Revenue rose from Rs 1,558 crore in FY22 to Rs 4,594 crore in FY26, a compound annual growth rate of 31.0%. Net profit grew from Rs 248 crore in FY22 to Rs 1,557 crore in FY26, which works out to a compound annual growth rate of 58.3%. In the June 2026 quarter, revenue grew 13.3% year on year to Rs 1,115 crore, while net profit rose 23.0% to Rs 394 crore. The company has a return on equity of 11.1%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 68,308 crore. The stock trades at a P/E of 41.9, above the industry P/E of 30.7. Looking ahead, the company is adding mall space and commercial assets as consumer spending rises. Rental income linked to footfall and consumption supports earnings as the portfolio matures.
How has LTM performed financially?
Ans. Revenue rose from Rs 26,874 crore in FY22 to Rs 43,402 crore in FY26, a compound annual growth rate of 12.7%. Net profit grew from Rs 3,950 crore in FY22 to Rs 4,983 crore in FY26, which works out to a compound annual growth rate of 6.0%. The company has a return on equity of 20.2%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 120,479 crore. The stock trades at a P/E of 23.2, above the industry P/E of 17.6. Looking ahead, the company is focused on cloud, data and artificial intelligence projects and on winning larger transformation deals from existing clients. Its link with the Larsen and Toubro group helps it reach large enterprise customers.
How has Molbio Diagnostics performed financially?
Ans. Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%. The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6. Looking ahead, its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.
What risks should investors check before buying mall, IT consulting and rapid test stocks?
Ans. Investors should check a few risks before buying mall, IT consulting and rapid test stocks. Consumer spending. Sales follow festivals, incomes and consumer mood. Client spending. Technology budgets can vary with global conditions. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of mall, IT consulting and rapid test stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 3 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
